VG2d pharMa

Innovation With Broader Reach

Cystic Fibrosis Therapeutic Innovation That Benefits As Many Patients As Possible

A comprehensive and accessible approach to the treatment of cystic fibrosis.

Innovative Approach

Our Patented Family of Molecules

Our patented family of molecules has a mechanism of action that opens new horizons in the treatment of Cystic Fibrosis.

We aim to treat cystic fibrosis beyond its respiratory symptoms and provide access to treatment to every patient suffering from the disease.

Proven Preclinical Efficacy

The VG2D Pharma molecules underwent multiple proof of concept experiments in vivo and in vitro.  The latter confirmed the mechanism of action, the efficacy and the safety of this family of molecules in the treatment of cystic fibrosis beyond respiratory symptoms.

Patient-Centric Design

The treatment

Our ambition is to improve patient experience with cystic fibrosis treatments. For that purpose, our treatment is an oral pill to be taken anytime during the day. Such dosing is intended to decrease the burden of the pill and improve adherence.

Dr. Imane Wild

CEO — PhD, MBA

Dr. Frédéric Velard

CSO Biologics — PhD

Prof. Stéphane Gérard

CSO Chemistry — PhD

Evolving Excellence

Our team

Meet the dedicated minds behind VG2D Pharma. Passionate, innovative, and driven to redefine the boundaries of healthcare.

Together We Achieve

A Collaborative Approach

We collaborate with public and private institutions to deliver first-class solutions in rare diseases and beyond.

Start A Conversation

Leave Us A Message